Advertisement
Postgraduate Education Corner Contemporary Reviews in Critical Care Medicine| Volume 144, ISSUE 2, P672-679, August 01, 2013

Management of Hyponatremia in the ICU

      Hyponatremia is common in critical care units. Avoidance of neurologic injury requires a clear understanding of why the serum sodium (Na) concentration falls and why it rises, how the brain responds to a changing serum Na concentration, and what the goals of therapy should be. A 4 to 6 mEq/L increase in serum Na concentration is sufficient to treat life-threatening cerebral edema caused by acute hyponatremia. In chronic (> 48 h), severe (< 120 mEq/L) hyponatremia, correction by > 8 to 10 mEq/L/d risks iatrogenic osmotic demyelination syndrome (ODS); therefore, a 4 to 6 mEq/L daily increase in serum Na concentration should be the goal in most patients. With the possible exception of hyponatremia caused by heart failure or hepatic cirrhosis, a rapid initial increase in serum Na for severe symptoms and avoidance of overcorrection are best achieved with 3% saline given in either a peripheral or central vein. Inadvertent overcorrection can be avoided in high-risk patients with chronic hyponatremia by administration of desmopressin to prevent excessive urinary water losses. In patients with hyponatremia with oliguric kidney failure, controlled correction can be achieved with modified hemodialysis or continuous renal replacement therapies. ODS is potentially reversible, even in severely affected patients who are quadriplegic, unresponsive, and ventilator dependent. Supportive care should be offered several weeks before concluding that the condition is hopeless.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Friedman B, Cirulli J. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V(2)-receptor antagonist tolvaptan. J Crit Care. In press. doi:10.1016/j.jcrc.2012.06.001.

        • Moritz ML
        • Ayus JC
        Dysnatremias in the critical care setting.
        Contrib Nephrol. 2004; 144: 132-157
        • Stelfox HT
        • Ahmed SB
        • Khandwala F
        • Zygun D
        • Shahpori R
        • Laupland K
        The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units.
        Crit Care. 2008; 12: R162
        • Nguyen MK
        Quantitative approaches to the analysis and treatment of the dysnatremias.
        Semin Nephrol. 2009; 29: 216-226
        • Edelman IS
        • Leibman J
        • O'Meara MP
        • Birkenfeld LW
        Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water.
        J Clin Invest. 1958; 37: 1236-1256
        • Sterns RH
        • Silver SM
        Cerebral salt wasting versus SIADH: what difference?.
        J Am Soc Nephrol. 2008; 19: 194-196
        • Steele A
        • Gowrishankar M
        • Abrahamson S
        • Mazer CD
        • Feldman RD
        • Halperin ML
        Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination.
        Ann Intern Med. 1997; 126: 20-25
        • Lin SH
        • Chau T
        • Wu CC
        • Yang SS
        Osmotic demyelination syndrome after correction of chronic hyponatremia with normal saline.
        Am J Med Sci. 2002; 323: 259-262
        • Sterns RH
        • Nigwekar SU
        • Hix JK
        The treatment of hyponatremia.
        Semin Nephrol. 2009; 29: 282-299
        • Sterns RH
        • Silver SM
        Brain volume regulation in response to hypo-osmolality and its correction.
        Am J Med. 2006; 119: S12-S16
        • Mount DB
        The brain in hyponatremia: both culprit and victim.
        Semin Nephrol. 2009; 29: 196-215
        • Sterns RH
        • Hix JK
        • Silver S
        Treating profound hyponatremia: a strategy for controlled correction.
        Am J Kidney Dis. 2010; 56: 774-779
        • Gankam Kengne F
        • Nicaise C
        • Soupart A
        • et al.
        Astrocytes are an early target in osmotic demyelination syndrome.
        J Am Soc Nephrol. 2011; 22: 1834-1845
        • Iwama S
        • Sugimura Y
        • Suzuki H
        • et al.
        Time-dependent changes in proinflammatory and neurotrophic responses of microglia and astrocytes in a rat model of osmotic demyelination syndrome.
        Glia. 2011; 59: 452-462
        • King JD
        • Rosner MH
        Osmotic demyelination syndrome.
        Am J Med Sci. 2010; 339: 561-567
        • Sterns RH
        • Riggs JE
        • Schochet Jr, SS
        Osmotic demyelination syndrome following correction of hyponatremia.
        N Engl J Med. 1986; 314: 1535-1542
        • Verbalis JG
        • Martinez AJ
        Neurological and neuropathological sequelae of correction of chronic hyponatremia.
        Kidney Int. 1991; 39: 1274-1282
        • Sterns RH
        • Thomas DJ
        • Herndon RM
        Brain dehydration and neurologic deterioration after rapid correction of hyponatremia.
        Kidney Int. 1989; 35: 69-75
        • Laureno R
        Central pontine myelinolysis following rapid correction of hyponatremia.
        Ann Neurol. 1983; 13: 232-242
        • Louis G
        • Megarbane B
        • Lavoué S
        • et al.
        Long-term outcome of patients hospitalized in intensive care units with central or extrapontine myelinolysis.
        Crit Care Med. 2012; 40: 970-972
        • Adrogué HJ
        • Madias NE
        Hyponatremia.
        N Engl J Med. 2000; 342: 1581-1589
        • Sterns RH
        • Hix JK
        • Silver S
        Treatment of hyponatremia.
        Curr Opin Nephrol Hypertens. 2010; 19: 493-498
        • Arieff AI
        Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women.
        N Engl J Med. 1986; 314: 1529-1535
        • Ayus JC
        • Achinger SG
        • Arieff A
        Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia.
        Am J Physiol Renal Physiol. 2008; 295: F619-F624
        • Halawa I
        • Andersson T
        • Tomson T
        Hyponatremia and risk of seizures: a retrospective cross-sectional study.
        Epilepsia. 2011; 52: 410-413
        • Sterns RH
        • Cappuccio JD
        • Silver SM
        • Cohen EP
        Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective.
        J Am Soc Nephrol. 1994; 4: 1522-1530
        • Sterns RH
        Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases.
        Ann Intern Med. 1987; 107: 656-664
        • Chow KM
        • Kwan BC
        • Szeto CC
        Clinical studies of thiazide-induced hyponatremia.
        J Natl Med Assoc. 2004; 96: 1305-1308
        • Koenig MA
        • Bryan M
        • Lewin III, JL
        • Mirski MA
        • Geocadin RG
        • Stevens RD
        Reversal of transtentorial herniation with hypertonic saline.
        Neurology. 2008; 70: 1023-1029
        • Bentsen G
        • Breivik H
        • Lundar T
        • Stubhaug A
        Hypertonic saline (7.2%) in 6% hydroxyethyl starch reduces intracranial pressure and improves hemodynamics in a placebo-controlled study involving stable patients with subarachnoid hemorrhage.
        Crit Care Med. 2006; 34: 2912-2917
        • Chawla A
        • Sterns RH
        • Nigwekar SU
        • Cappuccio JD
        Mortality and serum sodium: do patients die from or with hyponatremia?.
        Clin J Am Soc Nephrol. 2011; 6: 960-965
        • Arampatzis S
        • Frauchiger B
        • Fiedler GM
        • et al.
        Characteristics, symptoms, and outcome of severe dysnatremias present on hospital admission.
        Am J Med. 2012; 125: 1125e1-1125e7
        • Hoorn EJ
        • Rivadeneira F
        • van Meurs JB
        • et al.
        Mild hyponatremia as a risk factor for fractures: the Rotterdam Study.
        J Bone Miner Res. 2011; 26: 1822-1828
        • Verbalis JG
        • Barsony J
        • Sugimura Y
        • et al.
        Hyponatremia-induced osteoporosis.
        J Bone Miner Res. 2010; 25: 554-563
        • Renneboog B
        • Musch W
        • Vandemergel X
        • Manto MU
        • Decaux G
        Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.
        Am J Med. 2006; 119: 71.e1-71.e8
        • Barsony J
        • Manigrasso MB
        • Xu Q
        • Tam H
        • Verbalis JG
        Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats.
        Age (Dordr). 2013; 35: 271-288
        • Arieff AI
        • Llach F
        • Massry SG
        Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes.
        Medicine (Baltimore). 1976; 55: 121-129
        • Cluitmans FH
        • Meinders AE
        Management of severe hyponatremia: rapid or slow correction?.
        Am J Med. 1990; 88: 161-166
        • Vu T
        • Wong RF
        • Hamblin PS
        • Zajac JF
        • Grossmann MF
        Patients presenting with severe hypotonic hyponatremia: etiological factors, assessment, and outcomes.
        Hosp Pract (Minneap). 2009; 37: 128-136
        • Trissel LA
        Handbook on Injectable Drugs. 16th ed. American Society of Health-System Pharmacists, Bethesda, MD2011
        • Woo CH
        • Rao VA
        • Sheridan W
        • Flint AC
        Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment of acute neurologic hyponatremia.
        Neurocrit Care. 2009; 11: 228-234
        • Moritz ML
        • Ayus JC
        100 cc 3% sodium chloride bolus: a novel treatment for hyponatremic encephalopathy.
        Metab Brain Dis. 2010; 25: 91-96
        • Rogers IR
        • Hook G
        • Stuempfle KJ
        • Hoffman MD
        • Hew-Butler T
        An intervention study of oral versus intravenous hypertonic saline administration in ultramarathon runners with exercise-associated hyponatremia: a preliminary randomized trial.
        Clin J Sport Med. 2011; 21: 200-203
        • Lin SH
        • Hsu YJ
        • Chiu JS
        • Chu SJ
        • Davids MR
        • Halperin ML
        Osmotic demyelination syndrome: a potentially avoidable disaster.
        QJM. 2003; 96: 935-947
        • Mohmand HK
        • Issa D
        • Ahmad Z
        • Cappuccio JD
        • Kouides RW
        • Sterns RH
        Hypertonic saline for hyponatremia: risk of inadvertent overcorrection.
        Clin J Am Soc Nephrol. 2007; 2: 1110-1117
        • Perianayagam A
        • Sterns RH
        • Silver SM
        • et al.
        DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia.
        Clin J Am Soc Nephrol. 2008; 3: 331-336
        • Sterns RH
        • Hix JK
        Overcorrection of hyponatremia is a medical emergency.
        Kidney Int. 2009; 76: 587-589
        • Gowrishankar M
        • Chen CB
        • Mallie JP
        • Halperin ML
        What is the impact of potassium excretion on the intracellular fluid volume: importance of urine anions.
        Kidney Int. 1996; 50: 1490-1495
        • Berl T
        • Rastegar A
        A patient with severe hyponatremia and hypokalemia: osmotic demyelination following potassium repletion.
        Am J Kidney Dis. 2010; 55: 742-748
        • Licata G
        • Di Pasquale P
        • Parrinello G
        • et al.
        Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
        Am Heart J. 2003; 145: 459-466
        • Ambrosy A
        • Goldsmith SR
        • Gheorghiade M
        Tolvaptan for the treatment of heart failure: a review of the literature.
        Expert Opin Pharmacother. 2011; 12: 961-976
        • Gerbes AL
        • Gülberg V
        • Ginès P
        • VPA Study Group
        • et al.
        Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
        Gastroenterology. 2003; 124: 933-939
        • Sterns R
        • Hix J
        Hyponatremia: vasopressin antagonists in hyponatremia: more data needed.
        Nat Rev Nephrol. 2011; 7: 132-133
        • Velez JC
        • Dopson SJ
        • Sanders DS
        • Delay TA
        • Arthur JM
        Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
        Nephrol Dial Transplant. 2010; 25: 1524-1531
        • Huang WY
        • Weng WC
        • Peng TI
        • Ro LS
        • Yang CW
        • Chen KH
        Central pontine and extrapontine myelinolysis after rapid correction of hyponatremia by hemodialysis in a uremic patient.
        Ren Fail. 2007; 29: 635-638
        • Wendland EM
        • Kaplan AA
        A proposed approach to the dialysis prescription in severely hyponatremic patients with end-stage renal disease.
        Semin Dial. 2012; 25: 82-85
        • Lenk MR
        • Kaspar M
        Sodium-reduced continuous venovenous hemodiafiltration (CVVHDF) for the prevention of central pontine myelinolysis (CPM) in hyponatremic patients scheduled for orthotopic liver transplantation.
        J Clin Anesth. 2012; 24: 407-411